We studied the possible regulatory effects of 1␣,25-dihydroxyvitamin D 3 [1␣,25-(OH) 2 D 3 ] on cytokine production and differentiation of subsets of CD4 ϩ [T helper 1 (Th1) and Th2] and CD8 ϩ [T cytotoxic 1 (Tc1) and Tc2] lymphocytes at the single cell level. PBMC from healthy donors were cultured with or without 1␣,25-(OH) 2 D 3 for up to 21 days. On days 0, 7, 14, and 21, the percentage of cytokineproducing T lymphocytes was analyzed by intracellular cytokine detection with mAb and flow cytometry. Simultaneous staining for cell surface markers allowed discrimination of CD4 ϩ and CD8 ϩ T cell subsets. After culture with 1␣,25-(OH) 2 D 3 (10 Ϫ8 mol/L), no significant effects on the proportion of interferon-␥ (IFN␥)-or interleukin-4 (IL-4)-producing cells were detected, whereas reduced frequencies of IL-2-producing cells in the CD4 ϩ as well as in the CD8 ϩ population were
found. An increase in the low percentage of CD4 ϩ and CD8 ϩ T cells producing the Th2 cytokine IL-13 was noticed. Most interestingly, IL-6-producing CD4 ϩ and CD8 ϩ T cells could only be detected in cultures with 1␣,25-(OH) 2 D 3 , reaching a plateau after 14 days. The percentage of IL-6-producing T cells induced by 1␣,25-(OH) 2 D 3 after a given time period remained stable for at least 7 weeks. Studies of cytokine coexpression revealed that about 70% of IL-6-producing CD4 ϩ and CD8 ϩ cells were also positive for IL-2, but more than 90% were negative for IFN␥, IL-4, or IL-13, respectively. This suggests that the IL-6-producing population does not match the Th1/Tc1-like (IFN␥ ϩ ) or Th2/Tc2-like (IL-4 ϩ or IL-13 ϩ ) subset. The influence of 1␣,25-(OH) 2 D 3 on cytokine production by lymphocytes is probably an important point of intersection between the endocrine and the immune system. (J Clin Endocrinol Metab 84: 3739 -3744, 1999) H UMAN T cell responses have been attributed to two functionally distinct subsets on the basis of their cytokine production profiles (1) (2) (3) . T helper 1 (Th1) cells produce predominantly interferon-␥ (IFN␥) and interleukin-2 (IL-2), but little or no IL-4 and IL-5, whereas Th2 cells mainly produce IL-4 and IL-5. Whereas Th1 cells are involved in cell-mediated inflammatory reactions, Th2 cytokines encourage antibody production, particularly IgE responses, and enhance eosinophil proliferation and function. Accordingly, Th2 cells are found in association with strong antibody and allergic responses. Similar subsets exist in the CD8 ϩ population [cytotoxic T 1 (Tc1) and Tc2] (3-5). There is increasing evidence, that CD4 ϩ as well as CD8 ϩ T lymphocytes are collectively forming a continuous spectrum in which Th1/ Tc1 and Th2/Tc2 cells may be only two extremes of the possible phenotypes (6, 7) . Furthermore, cells producing high amounts of transforming growth factor-␤ have been described and classified as the Th3 subset (8) , indicating that the original concept is a simplification of the real situation. However, regardless of whether the variation in T cell cytokine synthesis represents a continuum or discrete subsets, the Th1-Th2 dichotomy remains an important functional division in the immune system and has been implicated in several immune responses concerning infections, allergy, and autoimmunity (reviewed in Ref. 3) .
A number of factors have been held responsible for the differentiation of Th1/Tc1 and Th2/Tc2 cells, including the dose of antigen, the type of antigen-presenting cell and/or of the costimulatory pathways (reviewed in Ref. 9) , as well as the local cytokine environment (reviewed in Refs. 10 and 11). Furthermore, the arachidonic acid metabolite PGE 2 (12) (13) (14) , and some members of the steroid hormone family, such as progesterone (15) (16) (17) , glucocorticoids (18, 19) (24) . Interference with cytokine production of monocytes and lymphocytes seems to be a key mechanism by which 1␣,25-(OH) 2 D 3 interacts with the immune system. Inhibition of secretion of IL-1, IL-2, IL-6, TNF, and IFN␥ (25) (26) (27) (28) (29) has been reported. Recently, a preferential inhibition of Th1 functions by the hormone has been suggested (20) . This opened a new point of view on a (patho)-physiological as well as pharmacological role of 1␣,25-(OH) 2 D 3 . However, the frequency as well as the precise pattern of cytokine (co)expression of the T lymphocyte populations that are generated by 1␣,25-(OH) 2 D 3 have not yet been defined. Such a clear definition is especially important with regard to a potential therapeutic application of vitamin D 3 compounds in Th1-mediated clinical situations such as autoimmunity and transplantation (30 -32) .
In the present study we therefore analyzed the regulation of cytokine production and coexpression in CD4 ϩ and CD8 
Materials and Methods

PBMC cultures
Healthy donors (four women and five men) were members of the laboratory staff and medical students, with an age range from 25-36 yr. PBMC were isolated from heparinized peripheral blood by density gradient centrifugation with Ficoll-Paque (Pharmacia, Uppsala, Sweden), and cultured in Ultra Culture Medium (BioWhittaker, Inc., Walkersville, MD). A schematic representation of the cell culture protocol is shown in Fig. 1 .
Cultures were initially stimulated for 3 days with 1% phytohemagglutinin (PHA; vol/vol; Life Technologies, Inc., Grand Island, NY). From day 3, PHA was replaced by IL-2 (20 U/mL; Genzyme, Boston, MA) to maintain cell proliferation and viability. 1␣,25-(OH) 2 D 3 (gift from Hoffmann La Roche, Basel, Switzerland) at a concentration of 10 Ϫ8 mol/L was present throughout the culture period (or absent in control cultures). On day 10, 10 mL fresh medium were added. Cells were analyzed for their cytokine-producing capability on day 0 and thereafter every 7 days.
Intracellular detection of cytokines
Flow cytometric assessment of T cell cytokine production was performed essentially by the technique described previously (33) . In brief, PBMC were isolated and cultured as described above. At the respective time points, cells were stimulated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA) and 1.25 mol/L ionomycin in the presence of 2 mol/L monensin (all from Sigma Chemical Co., St. Louis, MO) for 4 h. Cells were then harvested, washed, and fixed with 2% formaldehyde. Cells were permeabilized with 0.1% saponin (Sigma Chemical Co.) in phosphate-buffered saline. Four-color staining was performed, and cytokine production was analyzed in the CD4 ϩ and CD8 ϩ lymphocyte populations. Cytokine-specific rat or mouse anti-human mAb labeled with phycoerythrin [PE; IL-2(MQ1-17H12), IL-4 (8D4 -8), IL-6 (MQ2-13A5), and IL-13 (JES10 -5A2)] or fluorescein-isothiocyanate [FITC; IFN␥ (4S.B3)] as well as the respective isotype controls were obtained from PharMingen (San Diego, CA). To study the coexpression of IL-6 with IL-2, IL-4, and IL-13, a FITC-labeled anti-IL-6 mAb (PharMingen) was used. In this case, a polyclonal FITC-labeled rabbit anti-rat IgG conjugate (STAR17B, Serotec, Oxford, UK) had to be used as a second step reagent to reach sufficient signal intensity for IL-6. Percentages of IL-6-positive cells after optimal staining were similar with FITC and PE, and double staining controls confirmed that the population detected by both techniques was identical. The anti-CD4 mAb was labeled with allophycocyanin, and the anti-CD8 mAb was labeled with peridinin chlorophyll (Becton Dickinson and Co., Mountain View, CA). Figure 2 illustrates the gating strategy used to analyze cytokine (co-) expression in CD4 ϩ and CD8 ϩ lymphocytes. Cells were gated as lymphocytes by their light scatter characteristics and subsequently defined as CD4 ϩ and CD8 ϩ . Cells fulfilling both criteria (lymphocyte and CD4 ϩ or CD8 ϩ ) were further analyzed for their cytokine production pattern.
Quantification of IL-6 secretion by ELISA
At the indicated time points, 1.0-mL aliquots of each culture (n ϭ 5) were transferred to a 24-well plate and stimulated with 10 ng/mL phorbol 12-myristate 13-acetate and 1.25 mol/L ionomycin for 4 h. IL-6 concentrations in cell culture supernatants were determined with a Medgenix IL-6 EASIA kit (Biosource Technologies Europe S.A., Fleurus, Belgium), according to the protocol of the manufacturer.
Statistics
Data were analyzed using Student's t test (paired, two-tailed). Significance is expressed by P values (P Ͻ 0.05). Enzyme-linked immunosorbent assay (ELISA) data were analyzed using the Mann-Whitney rank sum test.
Results
Regulation of IL-2, IFN␥, IL-4, and IL-13 by 1␣,25-(OH) 2 D 3
Percentages of CD4 ϩ and CD8 ϩ cells from cultures with or without 1␣,25-(OH) 2 D 3 , producing the indicated cytokines are presented in Fig. 3 , and the relative effects of 1␣,25-(OH) 2 D 3 on the frequency of cytokine-producing lymphocytes are shown in Table 1 . On day 0, a significantly higher frequency of IL-2-producing cells was found within the CD4 ϩ (46.4 Ϯ 9.8%) compared to the CD8 ϩ (17.8 Ϯ 4.3%) population (P Ͻ 0.005). The rise in the frequency of IL-2-positive CD4
ϩ and CD8 ϩ cells we observed in control cultures on day 14 was completely blocked by 1␣,25-(OH) 2 D 3 (P Ͻ 0.005).
In contrast, frequencies of IFN␥-producing cells were significantly lower within the CD4 ϩ population on day 0 (13. 
Induction of an IL-6-producing T cell population by 1␣,25-(OH) 2 D 3
On day 0, IL-6-producing T cells were virtually absent, and only marginal frequencies could be detected in some experiments. Control cultures without 1␣,25-(OH) 2 D 3 remained negative at all time points tested. However, after treatment with 1␣,25-(OH) 2 D 3 , a significant proportion of CD4 ϩ [6.9 Ϯ 4.5% on day 7 (P Ͻ 0.01) and 14.0 Ϯ 9.2% on day 14 (P Ͻ 0.005)] and CD8 ϩ [2.2 Ϯ 1.8% on day 7 (P Ͻ 0.05) and 4.3 Ϯ 4.8% on day 14 (P Ͻ 0.05)] cells produced IL-6. The percentages of CD4 ϩ and CD8 ϩ cells producing IL-6, are presented in Fig. 3 (bottom) ; the relative effects of 1␣,25-(OH) 2 D 3 on the frequency of cytokine-producing lymphocytes are shown in Table 1 .
Experiments with culture periods of more than 3 weeks revealed that a plateau is reached on day 14 or, in some experiments, on day 21, with a maximum frequency of IL-6-producing CD4 ϩ cells of 20 -25% and of IL-6-producing CD8 ϩ cells of 10 -13% (data not shown). After having reached a plateau, the percentage of IL-6-positive cells remained stable for at least 62 days, which was the longest period tested (data not shown).
Coexpression of IL-6 with IL-2, IFN␥, IL-4, and IL-13
Simultaneous staining for the expression of IL-6, on the one hand, and IL-2, IFN␥, IL-4, or IL-13, on the other hand, was used to address the question of cytokine coexpression by CD4 ϩ and CD8 ϩ cells treated with 1␣,25-(OH) 2 D 3 for 14 days. As shown in Figs. 4 and 5, less than 10% of the IL-6-producing CD4 ϩ cells were also positive for IFN␥. Similarly, coexpression of IL-6 with IL-4 or IL-13 was less than 10% (Fig.  5) . In contrast, more than 70% of the IL-6-producing CD4 ϩ population coexpressed IL-2 (Figs. 4 and 5 ). Analogous to CD4 ϩ cells, few IL-6-producing CD8 ϩ cells coproduced IFN␥, IL-4, or IL-13. In the CD8 ϩ population, which exhibited a lower frequency of IL-2-positive cells, coexpression of IL-6 and IL-2 was lower than that in CD4 ϩ cells (Fig. 5) .
ELISA detection of IL-6
Culture supernatants were analyzed for secreted IL-6 after stimulation with phorbol 12-myristate 13-acetate and ionomycin for 4 h without the addition of monensin (n ϭ 5). On day 7, IL-6 could be detected in control cultures (43.2 Ϯ 24.2 pg/mL) as well as in cultures with 1␣,25-(OH) 2 D 3 (79.6 Ϯ 48.5 pg/mL). On day 14, virtually no production of IL-6 could be found in controls (4.0 Ϯ 4.7 pg/mL), whereas cultures treated with 1␣,25-(OH) 2 D 3 displayed significantly increased levels (113.8 Ϯ 102.2 pg/mL) of secreted IL-6 (P Ͻ 0.05). has been attributed to the ability of the steroid hormone to shift T cell responses from Th1 to Th2 (20) . Here we report for the first time how 1␣,25-(OH) 2 D 3 affects the frequency of cytokine-producing human peripheral blood T lymphocytes and induces a specific pattern of cytokine production in CD4 ϩ and CD8 ϩ T cells (for relative effects, see (34) . This suggests that suppression of IFN␥ production is an indirect effect of 1␣,25-(OH) 2 D 3 , probably mediated by inhibition of IL-12 secretion from costimulatory cells, such as monocytes, dendritic cells, or B cells (20, 35) . Endogenous production of IL-12 may not be an essential requirement for the appearance of IFN␥-producing T cells in our differentiation model. Therefore, no significant effect of 1␣,25-(OH) 2 D 3 was detectable. On the other hand, it has been suggested that inhibition of IL-12 secretion and subsequent suppression of the Th1 response drive the immune system toward Th2 function (36) . It has been reported that 1␣,25-(OH) 2 D 3 inhibits the secretion of IL-4 from Th0 cells only at an almost 10-fold higher concentration than necessary for inhibition of IFN␥ and does not inhibit IL-4 secretion by Th2 cells (20) . Although an increase in the frequency of IL-4-producing T cells was not significant in our experiments, there was a highly significant induction of the Th2-type cytokine IL-13, indicating that 1␣,25-(OH) 2 D 3 , may have the potency to directly enhance the development of a Th2 response, and not only via inhibition of Th1 reactions. IL-13 shares many biological activities with IL-4, although it does not act on T cells, as human T cells do not express the IL-13 receptor. IL-13 has been shown to inhibit the production of IL-1, IL-6, and tumor necrosis factor-␣ by activated monocytes and to enhance the synthesis of IL-1 receptor antagonist (37) . Recently, stimulation of IL-6 production by IL-13 has been demonstrated in human osteoblasts (38) .
IL-6 originally has been assigned the Th2-type cytokine (3). IL-6 is a pleiotropic cytokine involved in the regulation of immune responses, the acute phase response, and hemopoiesis (39) . Although initially thought to be a proinflammatory cytokine, recent findings suggest that IL-6 has many antiinflammatory and immunosuppressive effects (40) . There is substantial evidence that IL-6 and some of the IL-6 type cytokines (IL-11, leukemia inhibitory factor, and oncostatin M) have profound effects on bone metabolism by regulating osteoclast and osteoblast development and function (41) . IL-6 is produced by many different cells after stimulation during infection, trauma, or immunological challenge. In human peripheral blood, monocytes represent the primary source of IL-6 (42), although IL-6 production by a fraction of human peripheral blood T cell has been demonstrated (43, 44) . Inhibition of IL-6 production in human peripheral blood mononuclear cells (PBMC) as well as in partially purified monocytes, by 1␣,25-(OH) 2 D 3 has been reported (29, 24) . Others have described variable effects of 1␣,25-(OH) 2 D 3 on IL-6 secretion by human PBMC depending on the stimulus used (45) . However, data obtained from ELISA and bioassay analysis of bulk culture supernatants cannot be attributed to a specific cell type, and no information has been available to date about the regulation of IL-6 production by 1␣,25-(OH) 2 D 3 in T lymphocytes. We show that the frequency of IL-6-producing T cells is very effectively regulated by 1␣,25-(OH) 2 D 3 (see relative effects in Table 1) .
Monocytes are present in our cultures and are probably responsible for the detected levels of secreted IL-6 in supernatants from cultures with or without 1␣,25-(OH) 2 D 3 on day 7. Absolute and relative number of monocytes decline until day 14 (not shown); therefore, no IL-6 production was detectable in control cultures on day 14. In our flow cytometric analysis, monocytic cells were excluded by gating on CD4 and CD8, and T cell lineage of the gated cells was confirmed by control staining for CD3 (data not shown).
The production of IL-6 by activated CD4 ϩ and CD8 ϩ T cells in the presence of 1␣,25-(OH) 2 D 3 is not transient, and the frequency of positive cells remained stable for several weeks. As overlap with IFN␥, IL-4, or IL-13 production is negligible, IL-6-producing T cells may represent a specific subset within the continuum of Th and Tc phenotypes, with an as yet unknown role in the coupling of immune and endocrine system. Thus, the ability of 1␣,25-(OH) 2 D 3 to induce IL-6 production in human T lymphocytes could aid its efficiency as an anticancer agent, inasmuch as IL-6 released under the influence of the steroid hormone could stimulate the proliferation of tumor-infiltrating T lymphocytes (see, among others, Refs. 46 and 47) and thus enhance tumor-specific cytotoxic T cell responses. With respect to bone remodeling, it should be noted that induction of osteoclast-like cells by 1␣,25-(OH) 2 D 3 in naive mouse bone marrow cultures depends to a sizeable extent on costimulatory signals via the IL-6/IL-6 receptor pathway (48, 49) .
It is remarkable that 1␣,25-(OH) 2 D 3 regulates cytokine production in CD8 ϩ and CD4 ϩ T cells in parallel. This is in line with reports about the capacity of CD8 ϩ cells to produce Th1-and Th2-type cytokines and the possibility of triggering their differentiation into Tc1 and Tc2 with the same agents as CD4 ϩ cells (33, 50 -52) . Taken together, we show that 1␣,25-(OH) 2 D 3 induces differentiation of T cell populations with specific patterns of cytokine production. Reduced ability of T cells to produce IL-2 and increased percentages of cells capable of producing IL-13 or IL-6 are in line with the concept that 1␣,25-(OH) 2 D 3 acts as an immunomodulatory agent. Importantly, the fact that 1␣,25-(OH) 2 D 3 induces a stable, IL-6-producing T cell population could have far-reaching consequences for the involvement of both the steroid hormone and the cytokine in nonimmune systems such as control of tumor cell growth and bone remodeling. 
